|
Sep 12
|
Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference
|
|
Aug 7
|
Keros Therapeutics Reports Second Quarter 2024 Financial Results
|
|
Jun 17
|
Keros Therapeutics Announces Leadership Updates
|
|
Jun 17
|
Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association
|
|
May 14
|
Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association
|
|
May 10
|
Keros Therapeutics Reports Widening Losses in Q1 2024, Despite Progress in Clinical Trials
|
|
May 8
|
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
|
|
Apr 15
|
Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%?
|
|
Mar 14
|
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
|
|
Mar 5
|
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
|
|
Feb 12
|
Recent Price Trend in Keros Therapeutics, Inc. (KROS) is Your Friend, Here's Why
|
|
Jan 15
|
How Much Upside is Left in Keros Therapeutics, Inc. (KROS)? Wall Street Analysts Think 57.46%
|
|
Jan 9
|
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
|
|
Jan 4
|
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
|
|
Jan 3
|
Keros Therapeutics Announces Proposed Public Offering of Common Stock
|
|
Jan 3
|
Keros Therapeutics to Develop KER-065 for the Treatment of Obesity
|
|
Nov 6
|
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results
|
|
Nov 2
|
Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and Exposition
|
|
Sep 5
|
Keros Therapeutics to Present at Upcoming Healthcare Conferences
|